FilingReader Intelligence
Gland Pharma wins US approval for Cangrelor injection
August 12, 2025 at 07:29 AM UTC•By FilingReader AI
Gland Pharma Limited announced USFDA approval for its Cangrelor for Injection 50mg/vial, bioequivalent to KENGREAL and indicated as an adjunct to percutaneous coronary intervention.
The company is eligible for 180 days of generic drug exclusivity. The product had US sales of approximately $122 million for the twelve months ending June 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:GLAND•Bombay Stock Exchange
News Alerts
Get instant email alerts when Gland Pharma publishes news
Free account required • Unsubscribe anytime